CRC
REGN icon

Catawba River Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Catawba River Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,778
Closed -$13M – 25
2026
Q1 		$13M Sell
16,778
-12,566
-43% -$9.62M 6.27% 6
2025
Q4 		$22.6M Sell
29,344
-401
-1% -$272K 10.08% 3
2025
Q3 		$16.7M Buy
29,745
+69
+0.2% +$39K 7.59% 5
2025
Q2 		$15.6M Buy
29,676
+20,006
+207% +$11.2M 7.92% 4
2025
Q1 		$6.13M Buy
9,670
+391
+4% +$269K 3.73% 13
2024
Q4 		$6.61M Buy
9,279
+383
+4% +$321K 3.94% 13
2024
Q3 		$9.35M Buy
8,896
+27
+0.3% +$30K 5.91% 6
2024
Q2 		$9.32M Sell
8,869
-7,184
-45% -$6.96M 5.64% 5
2024
Q1 		$15.5M Sell
16,053
-136
-0.8% -$129K 9% 2
2023
Q4 		$14.2M Buy
16,189
+202
+1% +$166K 9.99% 2
2023
Q3 		$13.2M Buy
15,987
+14
+0.1% +$11K 10.14% 2
2023
Q2 		$11.5M Buy
15,973
+6,721
+73% +$5.18M 9.15% 2
2023
Q1 		$7.6M Sell
9,252
-3
-0% -$2.26K 6.91% 2
2022
Q4 		$6.68M Sell
9,255
-8
-0.1% -$5.9K 7% 5
2022
Q3 		$6.38M Buy
9,263
+85
+0.9% +$53.5K 7.6% 3
2022
Q2 		$5.42M Buy
9,178
+215
+2% +$140K 7.13% 6
2022
Q1 		$6.26M Buy
8,963
+11
+0.1% +$6.96K 4.15% 11
2021
Q4 		$5.65M Buy
8,952
+184
+2% +$113K 3.43% 18
2021
Q3 		$5.31M Buy
+8,768
New +$5.44M 3.34% 19

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Catawba River Capital's REGN Position: Q2 2026 in Review

Catawba River Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 16,778 shares — an estimated $13M sold.

Catawba River Capital first reported a position in REGN in Q3 2021 and held it in 19 quarters. The position peaked at $22.6M in Q4 2025. 1,327 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Catawba River Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Catawba River Capital sold 16,778 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $13M.
  • Catawba River Capital first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 19 quarters.
  • Catawba River Capital's Regeneron Pharmaceuticals position peaked at $22.6M in Q4 2025.
  • 1,327 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Catawba River Capital's 13F filing for Q2 2026, filed 22 Jul 2026.